Bernard Mulder has more than two decades of experience in the life sciences industry. He worked for Organon for 12 years, of which he spent 10 years abroad in Asia, Europe and the USA. He held several medical, marketing, sales and managerial positions in the different countries. After returning to the Netherlands, he worked as Global VP Marketing, Sales and Business Development for Avantium Pharma. In 2011, Bernard co-founded Eagle Rock Life Sciences to support life sciences enterprises from early start-ups to mature companies (hands-on) and also invested in start-ups. Most recently, he worked for Boehringer Ingelheim for the medical department. Bernard earned his medical degree at Leiden University and his MBA from New York Institute of Technology.
Frank P. Luyten, MD, PhD is board certified Rheumatologist, tenured full Professor and Head of the Division of Rheumatology at the University Hospitals Leuven; Director of the Skeletal Biology & Engineering Research Center, KU Leuven and of Prometheus, the Tissue Engineering Division at the KU Leuven. He obtained his MD, PhD degree and Board Certification in Rheumatology at the University of Ghent, Belgium. He spent his Postdoctoral Training at the National Institute of Dental Research, National Institutes of Health, Bethesda, MD, USA. He became subsequently group leader of the Developmental Biology Unit at the Bone Research Branch, NIDR, NIH, Bethesda, USA. Frank Luyten is also founder, scientific and medical advisor of TiGenix, a Biotech spin-off of the Universities of Leuven and Ghent. He serves as advisor and board member of several biotech companies in the field of Regenerative Medicine.
Marianne van der Steen is Professor of Entrepreneurship in Healthcare at the Technology-inspired Institute of Regenerative Medicine (MERLN), Faculty of Health, Medicine and Life Sciences, Maastricht University. She has been appointed director of RegMed XB and member of the board of governors of RegMed XB foundation. Marianne van der Steen received her PhD degree in 1999 from Twente University. Her research focus is on biomedical entrepreneurship, specifically on the scaling-up of ventures. At MERLN, she is responsible for biomedical entrepreneurship valorization, training and education from the lab to a spin-off company.
In addition, she is the founding director of executive life sciences entrepreneurship programs such as the Global Investor Forum, the Global Scale-up Program and the executive Master MBI Life Sciences & Health (currently member of the advisory board). Since 2006, she has been involved in life sciences start-ups, served in early stage start-up investor boards and national and international advisory boards related to entrepreneurship and valorization in the Netherlands, Belgium and the United States.
Melanie Wilms has worked in accountancy for about 10 years as a financial advisor to entrepreneurs and companies where management and ownership are in one hand. In addition, she has assisted companies with risk management, acquisitions, financing issues, and company valuations. After accountancy, Melanie started working in the insurance industry. Within a few years, she became a managing director and in this role, she was responsible for the day-to-day management of the company, the optimization of processes, as well as the preparation and implementation of several reorganizations. Subsequently, she acted as CFO of the group and in this position, she was responsible for reporting, (long-term) budgets, company valuation, optimization of cash flow management and financing structure, and acquisitions. We are very happy to welcome someone to our team with such extensive experience as financial advisor in the fields of reporting, risk management, and compliance.
Tom Mastenbroek is the Program Manager for RegMedXB. He studied biology at the University of Wageningen and during his master’s education he specialized in cellular differentiation and immunology. In 2016, he obtained his Ph.D. in the field of vascular biology, vessel wall remodelling and thrombosis & haemostasis at Maastricht University under the guidance of Dr. Judith Cosemans and Prof. Johan Heemskerk. In his thesis, he showed for the first time the potential of blood platelets to degrade extracellular matrix and the involvement of platelets in pathological remodelling of the vessel wall after an atherothrombotic event. This concept was further exploited during his PostDoc where he identified novel ways of inhibiting platelet dependent growth factor secretion aiming to block pathological vascular remodelling.
Lena Wijnen is a Project Leader at RegMedXB. She obtained a research master in Epidemiology at the University of Utrecht and a master in Healthcare Policy, Innovation and Management at the university of Maastricht. She gained experience with different academic research topics during various internships in the Netherlands and abroad.
Brenda Ferrer is a Project Leader at RegMedXB. She graduated from the Faculty of Communication at the University of Havana and continued her studies as an international affairs specialist for the Cuban Ministry of International Relations. She has office & project management experience working in different industries: news media, international organizations, tourism and TV distribution.
Maria Sol Cabrera is an Impact Officer at RegMed XB. She obtained a master’s degree in mechanical engineering from the National University of Mar del Plata and continued her academic career pursuing a master’s degree in material science at the Polytechnic University of Catalonia and the Technical University of Luleå. In 2015 she obtained a PhD degree from the Technical University of Eindhoven in the field of stent design and became a LifeScience entrepreneur, co-founding and directing a start-up company dedicated to the development of regenerative stents
Irene van Gorkom is the Office Assistant for RegMed XB. With her marketing assistant background in the pharmaceutical business and her organizational skills, she will be in charge of all our back-office tasks. She has taken an interest in healthcare years ago and at RegMed XB she has the opportunity to work in this field again.